Katkenov Nurlubek, Mukhatayev Zhussipbek, Kozhakhmetov Samat, Sailybayeva Aliya, Bekbossynova Makhabbat, Kushugulova Almagul
Laboratory of Microbiome, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Heart Center, CF "University Medical Center", Astana 010000, Kazakhstan.
J Cardiovasc Dev Dis. 2024 Jul 1;11(7):206. doi: 10.3390/jcdd11070206.
Cardiovascular diseases (CVDs) are a leading cause of global morbidity and mortality, significantly driven by chronic inflammation. Interleukin-6 (IL-6) and interleukin-1β (IL-1β) are critical inflammatory cytokines implicated in CVD progression. This systematic review evaluates the roles of IL-6 and IL-1β in CVDs by synthesizing data from relevant studies to understand their impact on cardiovascular outcomes and identify potential therapeutic interventions. A comprehensive literature search was conducted using PubMed and Embase, covering studies from January 2014 to December 2024. Inclusion criteria encompassed studies investigating IL-6 and/or IL-1β in CVDs, including human and relevant animal models, and reporting clinical outcomes, molecular mechanisms, or therapeutic interventions. Data extraction and quality assessment were performed independently by two reviewers. Our review included 12 studies focusing on the roles of IL-6 and IL-1β in various CVDs. Elevated IL-6 levels were significantly associated with peripheral artery disease, myocardial infarction, and heart failure, while IL-1β levels were linked to worse outcomes in coronary artery disease and heart failure. Meta-analyses indicated a significant association between higher IL-6 and IL-1β levels and increased risk of adverse cardiovascular events. These findings suggest that targeting IL-6 and IL-1β could offer promising therapeutic strategies for reducing inflammation and improving cardiovascular outcomes.
心血管疾病（CVDs）是全球发病和死亡的主要原因，慢性炎症起着重要推动作用。白细胞介素-6（IL-6）和白细胞介素-1β（IL-1β）是参与CVD进展的关键炎症细胞因子。本系统评价通过综合相关研究数据来评估IL-6和IL-1β在CVDs中的作用，以了解它们对心血管结局的影响并确定潜在的治疗干预措施。使用PubMed和Embase进行了全面的文献检索，涵盖2014年1月至2024年12月的研究。纳入标准包括在CVDs中研究IL-6和/或IL-1β的研究，包括人类和相关动物模型，并报告临床结局、分子机制或治疗干预措施。由两名 reviewers 独立进行数据提取和质量评估。我们的评价纳入了12项关注IL-6和IL-1β在各种CVDs中作用的研究。IL-6水平升高与外周动脉疾病、心肌梗死和心力衰竭显著相关，而IL-1β水平与冠状动脉疾病和心力衰竭的更差结局相关。荟萃分析表明，较高的IL-6和IL-1β水平与不良心血管事件风险增加之间存在显著关联。这些发现表明，针对IL-6和IL-1β可能为减轻炎症和改善心血管结局提供有前景的治疗策略。
